Tamtam Try Tamtam free
Fred Hutch logo

Fred Hutch account plan

Independent nonprofit cancer center

At a glance

Fred Hutch is a Seattle not-for-profit, NCI-designated comprehensive cancer center with $2,511,452 thousand of FY2025 revenues and 6,200+ staff.

Fred Hutchinson Cancer Center (Fred Hutch) is a Washington not-for-profit, 501(c)(3) corporation and an NCI-designated comprehensive cancer research center in Seattle, formed in April 2022 when Fred Hutchinson Cancer Research Center combined with the Seattle Cancer Care Alliance. It runs a clinically integrated adult oncology program with UW Medicine, combining patient care (a 20-bed licensed hospital, ambulatory cancer care, a proton facility and retail pharmacy) with sponsored research in cancer and infectious disease. In FY2025 (year ended June 30, 2025) total revenues and other support were $2,511,452 thousand, up from $2,064,034 thousand, against operating expenses of $2,428,690 thousand. It served 72K+ patients with 650+ health care providers, 460 faculty members and 6,200+ staff. Thomas J. Lynch Jr., MD is president and director.

Business units

Strategic priorities

Faster patient access
Chief medical officer Tom Purcell wants new patients on the schedule within 48 to 72 hours, by restructuring new-patient appointments and organising clinics in teams and pods supporting APPs and physicians.
Capacity growth in transplant and immunotherapy
Growth over the past four years has created bottlenecks; Fred Hutch is evaluating capacity in all areas with UW School of Medicine departments and aims to make Blood and Marrow Transplant and immunotherapy more efficient and larger.
AI in administration, research and the clinic
Fred Hutch coordinates the Cancer AI Alliance (CAIA), funded with more than $40 million from Amazon Web Services, Microsoft, NVIDIA, Deloitte and Slalom, pilots the Abridge ambient-listening tool for charting with UW and uses GI Genius in colonoscopies.
Survivorship and team-based care
A survivorship group is being embedded within each disease type, with a new medical director of Adult Medical Survivorship, and doctors and APPs are paired on patient groups in pods supported by nurses and pharmacy.
Recruiting scientists and growing the Seattle campus
Lynch says the downtown Seattle campus is solidified to enable growth, and recruiting top scientists is a daily topic with his senior leaders, with a focus on curative approaches to cancer.
Reaching underserved regions
Fred Hutch wants its data and care to reach the rural parts of Washington state, Alaska and Idaho.

Latest results

In FY2025 (year ended June 30, 2025) total revenues and other support rose to $2,511,452 thousand from $2,064,034 thousand (+21.7%, computed), driven by patient service revenue of $1,583,727 thousand. Operating expenses rose to $2,428,690 thousand from $2,102,011 thousand, with supplies and pharmaceuticals the fastest-growing line at $732,382 thousand versus $574,247 thousand. The change in net assets from operations turned positive at $82,762 thousand (FY2024: $(37,977) thousand), though the without-donor-restriction operating line was still a deficit of $(1,989) thousand. Cash and equivalents fell to $197,558 thousand from $311,887 thousand. The audited statements give no guidance.

Investments and deals

Capital expenditure
Additions to land, buildings, equipment and rental property were $255,477 thousand in FY2025, up from $120,156 thousand in FY2024; finance right-of-use assets rose to $112,038 thousand as two building finance leases were added.
Life-science real estate joint ventures
Fred Hutch invested $209,405 thousand for 70% stakes in two Alexandria joint ventures (ARE-Seattle No. 55 and No. 56), formed in September 2024 to own and operate life-science commercial property in Seattle.
Series 2025A bonds
On February 4, 2025 it issued $172,745 thousand of Series 2025A bonds for general corporate purposes and to defease the Series 2022E and Series 2014 bonds; long-term debt stands at $1,051,116 thousand.
Sloan Clinic and precision oncology
The South Lake Union outpatient complex, serving more than 60,000 patients per year, was renamed the Sloan Clinic after a gift that expands the Stuart and Molly Sloan Precision Oncology Institute.

Challenges and risks

Federal research funding exposure
About 84% of research revenue comes from federal agencies, and research grants and contracts already fell to $500,242 thousand from $542,770 thousand; Lynch calls federal funding his biggest concern.
Rising supply and pharmaceutical costs
Supplies and pharmaceuticals reached $732,382 thousand in FY2025 versus $574,247 thousand, and salaries, wages and benefits $856,251 thousand.
Capacity bottlenecks and change management
Growth has put pressure on bottleneck areas, and reshuffling clinical responsibilities into pods involves what Purcell describes as a lot of change management affecting daily jobs.
Payments to UW Medicine
Collaborative arrangement expense with UW Medicine rose to $78,943 thousand from $50,056 thousand, with a recorded long-term liability of $428,824 thousand.
Leverage and falling cash
Long-term debt of $1,051,116 thousand carries a 1.10 times debt service coverage covenant, while cash fell to $197,558 thousand.

What leadership says

“We're at a time now of amazingly fast discoveries, as long as we don't stop federal funding for research. That's my biggest concern.”

Thomas J. Lynch Jr., MD, President and Director · Seattle magazine interview, From Vision To Victory, August 14, 2025

“We're growing our profile in the curative approach to cancer. And that's what the next 50 years is all about.”

Thomas J. Lynch Jr., MD, President and Director · Seattle magazine interview, From Vision To Victory, August 14, 2025

“We want our patients, especially new patients, to be able to get on the schedule easily, within 48 to 72 hours.”

Tom Purcell, MD, MBA, Chief Medical Officer · Fred Hutch News Service Q&A, November 6, 2025

“Financial headwinds are looming, and there are changes in our research funding, so there is an increased burden on our clinicians to help support our mission.”

Tom Purcell, MD, MBA, Chief Medical Officer · Fred Hutch News Service Q&A, November 6, 2025

Where a supplier can help

Scheduling and patient-access tooling
Tied to the 48 to 72 hour new-patient access target: scheduling, intake and clinic-workflow tools that help restructure new-patient appointments and pod-based clinics.
Clinical and administrative AI
Tied to the AI priority: Fred Hutch already pilots ambient listening for charting and coordinates CAIA, so AI for documentation, scheduling, billing and data quality fits stated plans.
Supply chain and pharmacy cost control
Tied to the supplies and pharmaceuticals challenge: procurement, pharmacy and inventory services that slow the fastest-growing cost line.
Change management for the new care model
Tied to the team-based care and survivorship priorities: training and change-management support for clinicians moving into pods and survivorship groups.
Diversified research and philanthropy funding
Tied to the federal funding challenge: industry research partnerships and fundraising technology that reduce reliance on federal grants.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Fred Hutch?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Fred Hutch

What does Fred Hutch do?

Fred Hutch is a Seattle not-for-profit, NCI-designated comprehensive cancer center that combines cancer and infectious disease research with patient care. It runs a clinically integrated adult oncology program with UW Medicine.

What is Fred Hutch's revenue?

In FY2025 (year ended June 30, 2025) total revenues and other support were $2,511,452 thousand, of which patient services were $1,583,727 thousand (63.0%).

How many people work at Fred Hutch?

The 2025 Annual Report counts 650+ health care providers, 460 faculty members and 6,200+ staff.

Who leads Fred Hutch?

Thomas J. Lynch Jr., MD has been president and director since February 2020; Tom Purcell, MD, MBA is chief medical officer.

What is Fred Hutch's strategy?

It is expanding clinical capacity and new-patient access, growing transplant and immunotherapy, investing in AI through the Cancer AI Alliance, and focusing on curative approaches to cancer.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)